Description du projet
Un test de diagnostic in vitro précis pour la méningococcie
La méningococcie représente un grave problème de santé qui touche des millions de personnes chaque année. Toutefois, nous ne disposons pas de tests de diagnostic suffisamment rapides et précis. Pour répondre à ces lacunes, la société française BioSpeedia a développé un test de diagnostic in vitro non invasif, capable de détecter les sérotypes de l’agent pathogène. La grande sensibilité, spécificité et rapidité de ce test, couplées à sa rentabilité, offre un outil de diagnostic fiable pour la méningococcie, y compris pour les systèmes de soins de santé disposant de ressources limitées. Le projet MeningoSpeed, financé par l’UE, conduira une étude de faisabilité en vue de la commercialisation de ce test de diagnostic extrêmement prometteur, susceptible d’aider à mettre en place un traitement rapide et précoce des patients atteints de méningococcie, améliorant significativement l’issue clinique et réduisant la mortalité de la maladie.
Objectif
Meningococcal disease (MD), caused by Neisseria meningitidis serogroups (mainly ABCXWY), annually affects 1.2 million people worldwide (mainly children and young). Due to its high lethality (8-15% treated patients), permanent sequelae and epidemic potential, MD represents a major public health problem. Despite the societal burden, there is a lack of rapid and accurate diagnostic tools for timely and early treatment that results very costly for healthcare systems (e.g. direct costs valued in € 68 m/hospital/year). In response to the unmet need, BioSpeedia (spin-off from the Institute Pasteur, France) has vast experience in infectious diseases management and is developing the first-ever gold nanoparticle-based immunochromatographic test with demonstrated diagnostic capability for the six Nm serogroups. MeningoSpeed is a non-invasive, accurate (sensitivity and specificity >93%), rapid (<15 min vs PCR: 3h) and cost-competitive in vitro diagnostic test (€45 sample, at least 25 % cheaper than latex agglutination tests and PCR alternatives) for MD diagnosis. Our one-step solution will result on added value for patients, physicians and healthcare purchasers by improving disease monitoring in an accurate and timely fashion way, reducing deaths and sequelae. MeningoSpeed will provide healthcare systems with limited resources with a reliable and cost-effective diagnostic tool, leading to significant cost-savings. MeningoSpeed´s high accuracy and performance under a faster and cheaper cost make it a disruptive solution with great potential for commercial success in the growing point-of-care market (€33 B by 2022, CAGR 10%). Thus, MeningoSpeed is projected to be a profitable business opportunity and a core source of growth for the company (ca. €33 M of accumulated net profit during 2022-2026). A next feasibility study covering the technological, commercial and financial issues will enable us to finalize our business plan and secure our steps towards the successful market launch.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
75724 PARIS
France
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.